Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy
Movement Disorders Clinical Practice2020Vol. 7(4), pp. 440–447
Citations Over TimeTop 10% of 2020 papers
Lawren VandeVrede, Marian L. Dale, Scott Fields, M Frank, Emma Hare, Hilary W. Heuer, Kellie Keith, Mary Koestler, Peter A. Ljubenkov, Dana McDermott, Noelle Ohanesian, Jennifer C. Richards, Julio C. Rojas, Elisabeth H. Thijssen, Christine M. Walsh, Ping Wang, Amy Wolf, Joseph F. Quinn, Richard Tsai, Adam L. Boxer
Abstract
Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)